Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Four Carbocyclic Rings (e.g., Daunomycin, Etc.) Patents (Class 514/34)
  • Patent number: 10201523
    Abstract: The invention provides compositions comprising wilforlide A for overcoming drug resistance in cancer therapy, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods and compositions for treating a cancer are disclosed. The method administers to a patient in need thereof a combination of wilforlide A and a chemotherapeutic drug. Wilforlide A and chemotherapeutic drug are administered in a combined amount effective to treat the cancer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug alone.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: February 12, 2019
    Assignee: WESTERN UNIVERSITY OF HEALTH SCIENCES
    Inventors: Moses Sing Sum Chow, Ying Huang, Zhi Jun Wang
  • Patent number: 10196687
    Abstract: Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample at the protein or nucleic level. The expression of the gene or biomarker can be indicative of the lung tumor subtype as well as prognostic and predictive for therapeutic response. The compositions and methods provided herein are suited for analysis of gene or biomarker expression at the protein or nucleic acid level in paraffin-embedded tissues.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 5, 2019
    Assignee: University of North Carolina at Chapel Hill
    Inventors: David N. Hayes, Charles M. Perou, Philip Bernard
  • Patent number: 10144753
    Abstract: The invention relates to anthracycline derivative compounds for treating tumor diseases, and related methods, compositions, and kits.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: December 4, 2018
    Assignee: Produkem Molekulares Design GMBH
    Inventors: Christian R. Noe, Michael Sonntagbauer, Sébastien Queva, Ernst Urban
  • Patent number: 10098962
    Abstract: The present invention provides a glycosaminoglycan derivative in which a group derived from glycosaminoglycan and a group derived from a physiologically active substance having at least one of a carboxy group and a hydroxy group are coupled by covalent bond with a spacer therebetween, in which the spacer is selected in accordance with the decomposition rate of the covalent bond to the group derived from the physiologically active substance.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: October 16, 2018
    Assignee: Seikagaku Corporation
    Inventors: Kenji Miyamoto, Yosuke Yasuda, Hisayuki Takeuchi, Keiji Yoshioka
  • Patent number: 10100372
    Abstract: An RSV reporter strain that can be used for high-throughput drug discovery is disclosed. Also disclosed is a recombinant RSV vector that contains an RSV genome encoding the disclosed RSV reporter strain operably linked to an expression control sequence. Also disclosed is an infectious RSV virion produce by expression of the disclosed recombinant RSV vector in a host cell. Also disclosed is a recombinant nucleic acid that comprises an RSV F protein having an escape mutation operably linked to a heterologous expression control sequence. Also disclosed are methods of screening for antiviral agents using the disclosed RSV reporter strains.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: October 16, 2018
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Richard K. Plemper, Dan Yan
  • Patent number: 10091998
    Abstract: A tetrazolinone compound represented by formula (1): wherein R1 represents a C1-C6 alkyl group; R2, R3, and R4 are the same or different and represent a hydrogen atom; R5 represents a C1-C3 alkyl group optionally having one or more halogen atoms; Y represents #—C(RA 1 RA 2)—Z— in which left end and Q are bound to each other, and RA 1 and RA 2 each represents a hydrogen atom; Q represents a divalent C3-C10 carbocyclic group; X represents an oxygen atom; and A represents a C6-C10 aryl group, has excellent control activity against pests.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: October 9, 2018
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Koichiro Dota
  • Patent number: 10064883
    Abstract: The present invention relates to a pharmaceutical composition including Lipiodol and a molecule with anti-tumor activity and secondarily a hydroxyethyl starch. The present invention also relates to the use of the compositions according to the invention for treating cancer. According to one embodiment, the pharmaceutical composition according to the invention has between 0.004% and 0.2% by weight of idarubicin, between 0.38% and 2.25% by weight of hydroxyethyl starch and secondarily between 60% and 68% by weight of Lipiodol, and water for injection (or even physiological saline) in a quantity sufficient (q.s.) for 100%.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: September 4, 2018
    Assignee: GUERBET
    Inventors: Boris Guiu, Mathieu Boulin, Jean-Pierre Cercueil
  • Patent number: 10045951
    Abstract: The invention relates compositions and methods for treating pathological lung conditions using whole-grain flaxseed or flaxseed lignans. Specifically, the invention relates to the dietary use of flaxseed lignans.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: August 14, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Melpo Christofidou-Solomidou
  • Patent number: 9968570
    Abstract: The present invention provides, in part, compositions and methods for treating cancer using a combination of C6-ceramide and other anti-cancer agents in certain vesicles.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: May 15, 2018
    Assignee: Chemo-Enhanced LLC
    Inventor: Harold J. Wanebo
  • Patent number: 9931313
    Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing proliferative disorders, such as cancel-, that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include monotherapy with malate, or a derivative thereof, as well as combination therapy, such as malate, or a derivative thereof, combined with another therapeutic agent, such as a malic enzyme 2 inhibitor, an antineoplastic agent, a glycolysis inhibitor, an antiangiogenic agent, an immunomodulatory agent, an antibody, or a cytokine.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: April 3, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vikas P. Sukhatme, Jian-Guo Ren
  • Patent number: 9895385
    Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 20, 2018
    Assignee: INSMED INCORPORATED
    Inventors: Gina Eagle, Renu Gupta
  • Patent number: 9839634
    Abstract: It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequency, enabling treatment of high-titer infections without treatment failure due to spontaneous resistance. Accordingly, certain embodiments provide a composition comprising a rifamycin and a switch region inhibitor, as well as methods of use thereof.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 12, 2017
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Richard H. Ebright
  • Patent number: 9801922
    Abstract: The invention provides compositions and methods to treat cancer with an agent that increases reactive oxygen species (ROS) levels in cancer cell mitochondria (“an XTPP agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: October 31, 2017
    Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION, REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Douglas R. Spitz, Michael K. Schultz, Kyle Kloepping, Yueming Zhu, Nukhet Aykin-Burns, Max S. Wicha
  • Patent number: 9657047
    Abstract: A crystalline epirubicin hydrochloride and a method for its production are provided. The method for producing the crystalline epirubicin hydrochloride includes the steps: (a) providing epirubicin hydrochloride, (b) producing a mixture containing the provided epirubicin hydrochloride and at least one alcohol selected from the group 1-butanol, 2-butanol, and 1-pentanol, and (c) crystallizing epirubicin hydrochloride from this mixture.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: May 23, 2017
    Assignee: MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH
    Inventor: Tero Kunnari
  • Patent number: 9585855
    Abstract: The present invention relates to methods of treating the side effects of a toxic medical therapy using nitrated lipids. In particular, the methods comprise the use of nitrated fatty acids or esters thereof to treat side effects, including organ system damage, caused by chemotherapy, radiotherapy, and the administration of other toxic agents.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: March 7, 2017
    Assignee: The University of Utah Research Foundation
    Inventor: Tianxin Yang
  • Patent number: 9566333
    Abstract: An isolated DNA molecule comprising a fragment of the gene encoding the feline NIS is disclosed as well as methods of use thereof. Also provided are methods for rational diet design of food composition suitable for administration to feline companion animals afflicted with hyperthyroidism, comprising (a) accessing at least one database that comprises a first data set relating functional gene profile of a biofluid or tissue sample from an animal to physiological condition of the animal, where the functional gene profile is that of the feline NIS gene; (b) accessing at least one database that comprises a second data set relating effects of bioactive dietary components on the functional gene profile; (c) using an algorithm drawing on these data sets, processing input data defining physiological condition to derive a nutritional formula promoting wellness of a feline companion animal afflicted with hyperthyroidism; and (d) preparing a food composition based on the nutritional formula.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: February 14, 2017
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Jeffrey Brockman
  • Patent number: 9527880
    Abstract: Disclosed is a steviol glycoside referred to as rebaudioside D3. Rebaudioside D3 has five ?-D-glucosyl units connected to the aglycone steviol. Also disclosed are methods for producing rebaudioside D3, a UDP-glycosyltransferase fusion enzyme, and methods for producing rebaudioside D and rebaudioside E.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: December 27, 2016
    Assignee: Conagen Inc.
    Inventors: Guohong Mao, Venkata Sai Prakash Chaturvedula, Oliver Yu
  • Patent number: 9486466
    Abstract: The invention relates to a method for the treatment of triple negative breast cancer in a subject, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, and an effective amount of carboplatin, in combination with standard of care.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: November 8, 2016
    Assignee: AbbVie Inc.
    Inventor: Gary Gordon
  • Patent number: 9267934
    Abstract: Embodiments of the present invention include methods and compositions for ameliorating cancer. Some embodiments include methods and compositions for ameliorating pancreatic cancer targeting the CXCR4 receptor and the CXCL12 ligand.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: February 23, 2016
    Assignee: University of South Alabama
    Inventors: Seema Singh, Ajay P. Singh
  • Patent number: 9220720
    Abstract: A method for reducing arrhythmic risk associated with cardiomyopathy includes administering a composition containing NAD+ or a mitochondrial targeted antioxidant to an individual in need thereof.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: December 29, 2015
    Assignees: U.S. DEPARTMENT OF VETERANS AFFAIRS, THE BOARD OF TRUSTEES OF THE UNIV. OF ILLINOIS
    Inventor: Samuel C. Dudley, Jr.
  • Patent number: 9211301
    Abstract: A method for reducing arrhythmic risk associated with cardiomyopathy by improving conduction velocity, includes administering a composition containing NAD+ or a mitochondrial targeted antioxidant to an individual or person in need thereof.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: December 15, 2015
    Assignees: U.S. DEPARTMENT OF VETERANS AFFAIRS, THE BOARD OF TRUSTEES OF THE UNIV. OF ILLINOIS
    Inventor: Samuel C. Dudley, Jr.
  • Patent number: 9207243
    Abstract: Methods of treating cancer comprising administering inhibitors of glucose transporters (GLUTs) are provided. Methods of predicting whether a cancer will respond to treatment with a GLUT inhibitor also are provided.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: December 8, 2015
    Assignee: Northwestern University
    Inventors: Malathy Shanmugam, Samuel K. McBrayer, Steven T. Rosen
  • Patent number: 9192677
    Abstract: The present invention relates in general to the field of targeted drug delivery of anti-cancer drugs. More precisely, the present invention concerns polymer drug conjugates, namely, conjugates of poly(organo)phosphazenes and anti-cancer drugs, wherein the conjugates are suitable to selectively release anti-cancer drugs in tumor tissue. In addition, the present invention relates to a method for manufacturing such poly(organo)phosphazene molecule conjugates, to poly(organo)phosphazene molecule conjugates for use in medicine, in particular, to poly(organo)phosphazene molecule conjugates for use in the treatment of cancer, and to pharmaceutical compositions comprising such poly(organo)phosphazene molecule conjugates.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: November 24, 2015
    Assignee: JOHANNES KEPLER UNIVERSITÄT LINZ
    Inventors: Ian P. Teasdale, Ivo Nischanga, Oliver Brüggemann, Sandra Wilfert
  • Patent number: 9150649
    Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: October 6, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Rajeeva Singh, Yelena Kovtun, Sharon D. Wilhelm, Ravi V. J. Chari
  • Patent number: 9067920
    Abstract: The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof, that inhibits Chk1 and is useful in the treatment of cancer.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: June 30, 2015
    Assignee: Eli Lilly and Company
    Inventors: Sajan Joseph, Susanta Samajdar
  • Patent number: 9050578
    Abstract: The present invention provides a novel system and method for sulphur and metal removal from crude oil and all liquid fuel fractions to biofuels by means of ultrasonic cavitation to enhance chemical reactions of said contaminants with sodium or potassium methylate and a water/fluoride mix in separate stages obtaining a solid form which is filtered out by the use of a centrifuge system. The resulting fuel is molecularly stable and cleaner than regular fuels.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: June 9, 2015
    Inventors: Carlos Jose Gonzalez, Miguel Jimenez, Luis Fernando Gutierrez
  • Publication number: 20150147314
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 28, 2015
    Inventors: Wilfred Jefferies, Reinhard Gabathuler
  • Publication number: 20150148301
    Abstract: The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumour-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 28, 2015
    Inventors: Virginie Clement-Schatlo, Thomas Fessard, Damien Barbaras, Joana Matos, Erick Carreira
  • Publication number: 20150148307
    Abstract: The present invention is directed to methods of prognosing relapsed leukemia in a subject. These methods are based on the detection of one or more relapse-specific gene mutations in a patient sample. The present invention further relates to methods of preventing and treating relapse leukemia in a subject based on the determined prognosis of the subject.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 28, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: William L. Carroll, Julia A. Meyer
  • Publication number: 20150140124
    Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 21, 2015
    Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
  • Publication number: 20150140120
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptarmers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: October 3, 2014
    Publication date: May 21, 2015
    Applicant: ARCHEMIX LLC
    Inventors: Dilara McCauley, John L. Diener, Charles Wilson, Thomas Greene McCauley
  • Publication number: 20150139905
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 21, 2015
    Inventors: Dinesh Chimmanamada, Weiwen Ying
  • Publication number: 20150140125
    Abstract: Synergistic cancer therapy drug combinations include therapeutically effective amounts of at least one chemotherapeutic drug or agent with a fortified decoction dosage form comprising from about 10 mg to about 6,000 mg each of ?-sitosterol, isovanillin, and linolenic acid. The decoction dosage preferably includes plant extract(s) of the genus Arum fortified with effective amounts of ?-sitosterol, isovanillin, and linolenic acid not derived from the plant. The combination may be in various forms including aqueous dispersions, gels, ampules, powders, capsules, pills, or tablets, and are normally administered orally to patients. The anticancer combinations have therapeutic effects on cancerous tissue which are greater than the sum of the individual therapeutic effects of the fortified decoction dosage form and the at least one chemotherapeutic agent on the cancerous tissue.
    Type: Application
    Filed: November 17, 2014
    Publication date: May 21, 2015
    Inventors: Gene H. Zaid, Thomas W. Burgoyne, Lisa Stehno-Bittel, Mary Ann Lee-Stanislav
  • Publication number: 20150141359
    Abstract: Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.
    Type: Application
    Filed: January 19, 2015
    Publication date: May 21, 2015
    Inventors: Justin Scot Hanes, Peter Anthony Campochiaro, Jie Fu
  • Publication number: 20150140073
    Abstract: Drug delivery compositions are disclosed that include multimolecular assemblies that have heparosan polymer(s) attached thereto and therapeutic(s) (and/or potential therapeutic(s)) entrapped, carried, or otherwise bound in the multimolecular assemblies. Methods for producing and using the drug delivery compositions are also disclosed.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventor: Paul L. DeAngelis
  • Publication number: 20150132384
    Abstract: Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.
    Type: Application
    Filed: March 4, 2013
    Publication date: May 14, 2015
    Inventors: Xiao Yu Wu, Alireza Shalviri, Ping Cai
  • Publication number: 20150133768
    Abstract: The present invention includes drug-loaded, polymer nanoparticles and liposomes further incorporating a non-paramagnetic, bioorganic CEST agent. The CEST agent allows for an alternative approach to accomplish MR-compatible in vivo tracking of drug-loaded polymer nanoparticles and liposomes, including simultaneous multi-color mapping of more than one particle type, or of the same particle type delivered via two different routes (e.g., systemic versus local). Additionally, the present invention can include a library of biodegradable diamagnetic (DIA)CEST agents. These DIACEST agents can be incorporated into nanoparticle-based delivery systems, such as stealth liposomes loaded with doxorubicin and stealth polymer nanoparticles loaded with paclitaxel. These systems can be tracked, according to an embodiment of the present invention using CEST-based MRI (compared to SPECT/CT) as a method to monitor the efficiency with which the nanoparticles reach the targeted tumors and how long they persist.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 14, 2015
    Inventors: Michael T. McMahon, Kannie W.Y. Chan, Guanshu Liu, Jeff W.M. Bulte, Nikita Oskolkov
  • Publication number: 20150132408
    Abstract: The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.
    Type: Application
    Filed: June 20, 2013
    Publication date: May 14, 2015
    Inventors: Robert H. Weiss, Bruce D. Hammock, Hiromi Inoue, Sung Hee Hwang
  • Patent number: 9023787
    Abstract: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: May 5, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Michael B. Yaffe, Isaac A. Manke, Hans Christian Reinhardt
  • Publication number: 20150118322
    Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 30, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Ya-Chin LO, Hsiang-Fa LIANG, Ming-Cheng WEI, Maggie J.M. LU, Min-Ying LIN, Chih-Peng LIU, Chun-MIN LIU, Hsiang-Wen TSENG, Tse-Min TENG, Jui-Hsiang CHEN, Yi-Man CHOU, Yi-Ting HSIEH, Chia-Mu TU
  • Publication number: 20150118248
    Abstract: The application describes a method of screening for breast cancer by testing fro the amount of HAGE (Helicase antigen) in a sample of breast tissue. Methods of prognosis of samples of breast cancer tumours are also provided. HAGE+ ER? (estrogen receptor-) cancers are indicated as being amenable to chemotherapy. Methods of treating breast cancers with HAGE-specific CTA antigen or HAGE-specific antibodies are also provided.
    Type: Application
    Filed: March 27, 2013
    Publication date: April 30, 2015
    Inventors: Adam Linley, Morgan Mathieu, Stephanie Mcardle, Chungui Lu, Robert Rees
  • Publication number: 20150110897
    Abstract: This disclosure provides a method for determining if a patient is likely to, or not likely to, experience ovarian cancer utilizing SP17 as a biomarker. It also provides methods and therapies to treat patients identified as at risk for ovarian cancer or alternatively, as identified as having a poorer prognosis.
    Type: Application
    Filed: September 12, 2012
    Publication date: April 23, 2015
    Applicants: University of Southern California, Texas Tech University System
    Inventors: Wijbe Martin Kast, Maurizio Chiriva-Internati
  • Publication number: 20150104384
    Abstract: The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Application
    Filed: March 1, 2013
    Publication date: April 16, 2015
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Janet Gunzner-Toste, Bingsong Han, Jian Lin, Xiongcai Liu, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Mark Zak, Yamin Zhang, Guiling Zao, Xiaozhang Zheng, Po-Wai Yuen
  • Publication number: 20150104416
    Abstract: A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventor: Dennis Brown
  • Publication number: 20150104526
    Abstract: The present invention relates to substituted imidazopyridazine compounds of general formula I in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: March 11, 2013
    Publication date: April 16, 2015
    Inventors: Marcus Koppitz, Ulrich Klar, Antje Margret Wengner, Roland Neuhaus, Gerhard Siemeister
  • Publication number: 20150099001
    Abstract: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.
    Type: Application
    Filed: September 8, 2014
    Publication date: April 9, 2015
    Inventors: Shiladitya Sengupta, Ganlin Zhao, Ishan Capila, David Eavarone, Ram Sasisekharan
  • Publication number: 20150094274
    Abstract: The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventors: Peter Wisdom Atadja, Wenlin Shao, Kapil N. Bhalla
  • Publication number: 20150093328
    Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
    Type: Application
    Filed: April 17, 2013
    Publication date: April 2, 2015
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Thomas Wickham, Bart S. Hendricks, Samuel Agresta, Helen Lee
  • Publication number: 20150086608
    Abstract: A porous polymeric matrix and a device for optically-controlled release of chemicals allow a controlled and localized administration of a chemical species, by exploiting the thermosensitivity of amphiphilic supramolecular structures used as reservoir without this requesting a direct heating, at the same time by guaranteeing a precise dosage and positioning of the release of the chemical species.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 26, 2015
    Applicant: CONSIGLIO NAZIONALE DELLE RICERCHE
    Inventors: Paolo Matteini, Fulvio Ratto, Roberto Pini
  • Publication number: 20150086551
    Abstract: The present invention relates to a class of hydroxamic acid compounds of Formula (I), which act as alkylating agents and/or inhibitors of the HDAC pathway, having potential utility in the treatment of a neoplastic disease and immune diseases.
    Type: Application
    Filed: January 31, 2013
    Publication date: March 26, 2015
    Inventors: Yu Chen, Yi Chen